CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Talon Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Talon Therapeutics Inc
Suite 200, 400 Oyster Point Blvd
Phone: (650) 588-6404p:650 588-6404 SOUTH SAN FRANCISCO, CA  94080  United States Fax: (650) 588-2787f:650 588-2787
This company ceased filing statements with the SEC on 7/29/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Talon Therapeutics, Inc. is a California-based biopharmaceutical company. The Company is engaged in developing and commercializing new and differentiated cancer therapies designed to improves and enable current standards of care. The Company's two product candidates target big markets. The Company is developing Marqibo for the treatment of acute lymphoblastic leukemia and other bloods cancers including lymphoma. The Company is also developing menadione topical lotion, a first-in-class compound, for the potential prevention and/or treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The Company, as of December 31, 2011, had rights to the product candidates in various stages of development.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201312/31/2012YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Leon E.Rosenberg 80 3/30/2007 2/1/2004
President, Chief Executive Officer, Director Steven R.Deitcher 47 8/24/2007 5/14/2007
Chief Financial Officer, Senior Vice President Craig W.Carlson 64 1/12/2011 4/1/2010
5 additional Officers and Directors records available in full report.

Business Names
Business Name
EMAIL REAL ESTATE COM INC
EMAIL REAL ESTATE COM INC
Email Real Estate.Com Inc
4 additional Business Names available in full report.

General Information
Number of Employees: 24 (As of 12/31/2012)
Outstanding Shares: 22,001,891 (As of 5/14/2013)
Shareholders: 110
Stock Exchange: OTC
Federal Tax Id: 320064979
Fax Number: (650) 588-2787
Email Address: info@talontx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023